Compare S&P500 ETF (SPY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs Viatris Inc — how do they compare? S&P500 ETF trades at $747.91, while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals.
| SPY | VTRS | |
|---|---|---|
52-Week High | $759.55 | $17.39 |
52-Week Low | $621.75 | $8.74 |
Market Cap | — | $19.79B |
Sector | — | Health |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY trades at $742.21, down 0.13% with a bearish technical outlook. The S&P 500 index faces pressure, declining 1.6% last week and trading below its 50-day moving average. Recent news highlights concerns about market concentration in tech stocks and elevated valuations, though some analysts see potential for continued gains. A dividend of $1.90 is scheduled for July 2026.
The ETF's outlook is mixed amid technical weakness and valuation debates. While earnings season shows strength, market concentration and fee comparisons with sister funds present risks. The bearish technical signal suggests near-term caution, though long-term index exposure remains a core portfolio strategy for many investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
